Ribo-regulators that sense trace antibiotics

Informations projet

DrugSense

N° de convention de subvention: 704340

DOI

10.3030/704340

Projet clôturé

Date de signature de la CE 21 Avril 2016

Date de début 1 Mai 2016

Date de fin 30 Avril 2017

Financé au titre de

• EXCELLENT SCIENCE - European Research Council (ERC)

Coût total

€ 150 000,00

Contribution de l’UE

€ 150 000,00

Coordonné par

WEIZMANN INSTITUTE OF SCIENCE
Israel

Periodic Reporting for period 1 - DrugSense (Ribo-regulators that sense trace antibiotics)

Période du rapport: 2016-05-01 au 2017-04-30

Résumé du contexte et des objectifs généraux du projet

The DrugSense project was aimed at commercializing the technology developed at the Sorek lab at the Weizmann Institute of Science, covered under U.S. provisional patent application 62/200,662. As planned, the expenses were used to cover the commercialization efforts as well as proof of concept experiments. These efforts resulted in the commercialization of the technology, which was eventually licensed by BiomX, a company developing novel therapeutics to alleviate microbiome-related diseases.


There is no overlap between the time that the PI dedicate to this project- DraugSense and the time that the PI dedicate to project PROKRNA.